PRIMECAP Odyssey Growth (POGRX)

40.75 -0.02  -0.05% Aug 10 USD
View Full Chart
Total Returns Chart

Key Stats

Net Asset Value 40.75
Turnover Ratio 6.00%
1 Year Fund Level Flows -4.020B

Performance & Returns

  Total Return Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M 2.67% 3.73% 75
3M 15.18% 17.86% 82
6M -1.81% 9.97% 95
YTD -0.46% 17.13% 97
1Y 12.48% 27.79% 93
3Y 11.54% 18.86% 94
5Y 10.93% 14.16% 82
10Y 13.88% 15.14% 71
15Y 10.46% 10.29% 46
20Y -- 6.42% --
As of Aug. 10, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 1.24% 1.24% 0.00%
Stock 98.76% 98.76% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of June 30, 2020

Region Exposure

Americas 84.29%
North America 84.29%
Latin America 0.00%
Greater Europe 8.26%
United Kingdom 2.17%
Europe Developed 5.54%
Europe Emerging 0.00%
Africa/Middle East 0.55%
Greater Asia 7.45%
Japan 1.48%
Australasia 0.00%
Asia Developed 1.30%
Asia Emerging 4.67%
Market Classification
% Developed Markets 95.33%
% Emerging Markets 4.67%
As of June 30, 2020. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.35%
Communication Services 4.03%
Consumer Cyclical 7.71%
Consumer Defensive 0.14%
Energy 1.71%
Financial Services 7.83%
Healthcare 37.30%
Industrials 11.68%
Real Estate 0.00%
Technology 29.26%
Utilities 0.00%
As of June 30, 2020

Stock Market Capitalization

Giant 31.53%
Large 27.29%
Medium 33.87%
Small 7.23%
Micro 0.08%
As of June 30, 2020

Stock Style Exposure

Large Cap Value 17.37%
Large Cap Blend 19.91%
Large Cap Growth 21.81%
Mid Cap Value 9.93%
Mid Cap Blend 11.00%
Mid Cap Growth 12.70%
Small Cap Value 0.57%
Small Cap Blend 2.16%
Small Cap Growth 4.55%
As of June 30, 2020
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
LLY Eli Lilly and Co 4.08% 151.48 -0.99%
SGEN Seattle Genetics Inc 3.52% 153.49 -2.67%
ABMD Abiomed Inc 3.27% 294.87 -1.72%
BMRN Biomarin Pharmaceutical Inc 2.67% 116.84 -1.19%
BIIB Biogen Inc 2.57% 291.00 -3.08%
SPLK Splunk Inc 2.56% 195.64 -1.14%
AMGN Amgen Inc 2.54% 234.83 -1.40%
BABA Alibaba Group Holding Ltd ADR 2.47% 248.75 +0.25%
ETFC E*TRADE Financial Corp 2.39% 53.82 +2.30%
MU Micron Technology Inc 2.31% 47.88 -2.58%
As of June 30, 2020
Advertisement

Basic Info

Investment Strategy
The investment seeks to provide long-term capital appreciation. The fund invests primarily in the common stocks of U.S. companies, emphasizing those companies with the potential for above average earnings growth. It may invest in stocks across all market sectors and market capitalizations. Although it has historically invested primarily in large- and mid-capitalization companies, it has also invested a significant portion of its assets in small-capitalization stocks.
General
Security Type Mutual Fund
Oldest Share Symbol POGRX
Equity Style Large Cap/Growth
Fixed Income Style --
Broad Asset Class US Equity
Broad Category Equity
Category Name Large Growth
Prospectus Objective Growth
Fund Owner Firm Name PRIMECAP Odyssey Funds
Benchmark Index
S&P 500 TR USD 100.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Alfred Mordecai 15.76 yrs
James Marchetti 5.75 yrs
Joel Fried 15.76 yrs
M. Ansari 8.31 yrs
Theo Kolokotrones 15.76 yrs

Net Fund Flows

1M -389.27M
3M -1.124B
6M -2.589B
YTD -2.830B
1Y -4.020B
3Y -2.084B
5Y -982.59M
10Y 1.670B
As of July 31, 2020

Risk Info

Beta (5Y) 1.162
Historical Sharpe Ratio (10Y) 0.8211
Historical Sortino (All) 0.6755
Daily Value at Risk (VaR) 1% (All) 3.65%
Monthly Value at Risk (VaR) 1% (All) 17.41%

Fundamentals

Dividend Yield TTM (8-10-20) 0.50%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio 20.54
Weighted Average Price to Sales Ratio 1.661
Weighted Average Price to Book Ratio 3.101
Weighted Median ROE 15.69%
Weighted Median ROA 4.08%
Forecasted Dividend Yield 1.34%
Forecasted PE Ratio 22.53
Forecasted Price to Sales Ratio 1.493
Forecasted Price to Book Ratio 2.750
Number of Holdings 153
As of June 30, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth 10.20%
Forecasted Book Value Growth 3.01%
Forecasted Cash Flow Growth 7.05%
Forecasted Earnings Growth 7.60%
Forecasted Revenue Growth 6.78%
As of June 30, 2020

Comparables

Edit

Attributes

Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment 2000.00 USD
Minimum Subsequent Investment 100.00 USD
Fees
Actual 12B-1 Fee --
Actual Management Fee 0.55%
Administration Fee --
Performance Fee --
Switching Fee --
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
Key Dates
Inception Date 11/1/2004
Termination Date
Last Annual Report Date 10/31/2019
Last Prospectus Date 2/28/2020
Attributes
Exchange Traded Share No
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.